FDA objects to statement that esterified estrogens are a "natural" alternative to Wyeth-Ayerst's Premarin (conjugated estrogens) in brochures, a press kit entitled "A New Option for Preventing Osteoporosis" and a B-roll video. The statement is an implied superiority claim, FDA contends in April 7 letter. In addition, suggestions in Solvay's Estratab video that the .3 mg dose is not associated with a risk of endometrial hyperplasia are lacking in fair balance because women take estrogens chronically for osteoporosis; the risk of hyperplasia "would be expected to increase with the duration of use," FDA says
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth